List view / Grid view
A recent whole genome sequencing study has revealed hidden insights into the causes of cancer. In an exclusive article, Dr Andrea Degasperi from the Early Cancer Institute at the University of Cambridge, UK spoke to Drug Target Review's Ria Kakkad about the study's implications and the future of whole genome sequencing.
4 January 2016 | By Victoria White
Vertex Pharmaceuticals is to use Genomic’s integrated database and state-of-the-art analysis tools to identify target therapeutic pathways...
5 October 2015 | By Victoria White
Biogen will leverage findings from Genomics’ integrated database and analysis tools, which will be used to guide drug research and development...
29 September 2015 | By Victoria White
Congenica’s platform Sapientia has been developed to analyse and interpret whole genome data. With this grant Congenica will be able to extend its capability to include other types of -omics data...
31 March 2015 | By Victoria White
AstraZeneca has joined with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project...
